ReviewInfection & chemotherapy2016
Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
Review in Infection & chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2023Pooled it
- Dose optimization of vancomycin in obese patients: A systematic review.Frontiers in pharmacology · 2023Pooled it
- Fibrin barriers limit vancomycin penetration into staphylococcal abscess communities and maintainbioRxiv : the preprint server for biology · 2026Article
- Chitosan-coated silver nanoparticles amplify glycopeptide efficacy againstFrontiers in microbiology · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Endophytic fungi as a source of antimicrobial compounds against emerging methicillin-resistantMycology · 2026Review
- Antimicrobial Peptide-Loaded Mesoporous Silica Nanoparticles: A pH-Triggered Controlled Release against Biofilms.ACS omega · 2025Article
- Histopathological changes and inflammatory and cell death pathways in the lungs of Balb/c mice with pneumonia induced by different concentrations ofAnatomy & cell biology · 2025Article
- Review
- The Ligand Binding Domain of the Cell Wall Protein SraP Modulates Macrophage Apoptosis and Inflammatory Responses inMolecules (Basel, Switzerland) · 2025Article
- Risk of Postoperative Infection in Total Knee Arthroplasty Patients with Preoperative Methicillin-ResistantJournal of clinical medicine · 2025Article
- Exploring caffeine as a disruptor of membrane integrity and genomic stability in Staphylococcus aureus: functional and in silico analysis.Archives of microbiology · 2025Article
- A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistantPharmaceutical nanotechnology · 2025Review
- Article
- An optimal antibiotic selection framework for Sepsis patients using Artificial Intelligence.NPJ digital medicine · 2024Article
- Multiomics analysis of Staphylococcus aureus ST239 strains resistant to virulent Herelleviridae phages.Scientific reports · 2024Article
- Sodium Alginate Microneedles Loaded with Vancomycin for Skin Infections.Journal of functional biomaterials · 2024Article
- Recent Advances in the Development of Antibiotics-Coated Gold Nanoparticles to Combat Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Nanosecond pulsed electric fields increase antibiotic susceptibility in methicillin-resistantMicrobiology spectrum · 2024Article
- PDADMAC/Alginate-Coated Gold Nanorod For Eradication of Staphylococcus Aureus Biofilms.International journal of nanomedicine · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.